[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648457":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":10,"responsibleParty":34,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":10,"studyType":51,"phases":10,"briefSummary":52,"conditions":53,"keywords":10,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":10},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"lupus nephritis group",null,"Inclusion criteria for LN group:\n\n1. Adult patients (≥ 18 and \\> 60 years) of either sex.\n2. Fulfill the 2019 EULAR\u002FACR Classification Criteria for Systemic Lupus Erythematosus (SLE) \\[11\\].\n3. Diagnosis of active lupus nephritis requiring a renal biopsy as per standard clinical indications (e.g., proteinuria ≥ 0.5 g\u002F24h, active urinary sediment, unexplained rise in serum creatinine).\n4. Availability of an adequate renal biopsy specimen for histopathological evaluation according to the International Society of Nephrology\u002FRenal Pathology Society (ISN\u002FRPS) 2018 classification.\n5. Patients planned to initiate standard induction therapy (e.g., mycophenolate mofetil or cyclophosphamide with corticosteroids).\n6. Provision of written informed consent.",[13],"Diagnostic Test: Serum Neutrophil Extracellular Traps",{"label":15,"type":10,"description":16,"interventionNames":17},"control group","Inclusion Criteria for Control Groups:\n\n1\\) SLE without nephritis: Patients meeting SLE criteria without any clinical or laboratory evidence of renal involvement (normal urinalysis, proteinuria \\\u003C 0.3 g\u002F24h, normal serum creatinine).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Serum Neutrophil Extracellular Traps","Serum sample should be collected into a serum separator tube. After clotting for 2 hours at room temperature or overnight at 4°C, and then centrifuging at 1000 × g for 20 minutes. Assay freshly prepared serum immediately or store samples in aliquot at -20°C or -80°C for later use. Avoid repeated freeze-thaw cycles.",[15,9],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Salwa Salah elgendi, MD","CONTACT","+0201005766155","salwaelgendi@aun.edu.eg",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Mai Mostafa Mohamed, MD","+0201223971678","mai_heamatology@aun.edu.eg",{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Hadeer S. Hassan","principle investigator","100648457","neutrophil-extracellular-traps-and-lupus-nephritis-100648457",false,"NCT07721857","Neutrophil Extracellular Traps and Lupus Nephritis","Dynamic Changes of Neutrophil Extracellular Traps in Lupus Nephritis and Their Role in Predicting Treatment Response.","Inclusion criteria for LN group:\n\n1. Adult patients (≥ 18 and \\> 60 years) of either sex.\n2. Fulfill the 2019 EULAR\u002FACR Classification Criteria for Systemic Lupus Erythematosus (SLE) \\[11\\].\n3. Diagnosis of active lupus nephritis requiring a renal biopsy as per standard clinical indications (e.g., proteinuria ≥ 0.5 g\u002F24h, active urinary sediment, unexplained rise in serum creatinine).\n4. Availability of an adequate renal biopsy specimen for histopathological evaluation according to the International Society of Nephrology\u002FRenal Pathology Society (ISN\u002FRPS) 2018 classification.\n5. Patients planned to initiate standard induction therapy (e.g., mycophenolate mofetil or cyclophosphamide with corticosteroids).\n6. Provision of written informed consent.\n\nInclusion Criteria for Control Groups:\n\n1\\) SLE without nephritis: Patients meeting SLE criteria without any clinical or laboratory evidence of renal involvement (normal urinalysis, proteinuria \\\u003C 0.3 g\u002F24h, normal serum creatinine).\n\nExclusion Criteria:\n\n* Participants will be excluded if ANY of the following criteria apply:\n\n  1. Other Kidney Diseases:\n\n     * Presence of, or suspicion of, any other primary or significant secondary kidney disease unrelated to SLE (e.g., diabetic nephropathy, hypertensive nephrosclerosis, IgA nephropathy, significant drug-induced nephrotoxicity, rheumatoid arthritis, positive HBs antigen or HCV antibody).\n  2. Confounding Clinical Conditions:\n\n     * Presence of an active or recent major infection (e.g., sepsis, pneumonia, UTI) at the time of enrollment, as infection can significantly alter immune markers.\n     * Presence of advanced chronic kidney disease (CKD Stage 4 or 5) predating the diagnosis of SLE.\n\n       3 · Pregnancy or lactation.\n\n  4\\. Recent use (within the last 3 months) of biologic therapies that may affect neutrophil function or NET formation.\n\n  5\\. Use of medications known to significantly alter neutrophil activity. 6. History of malignancy.","ALL","18 Years","60 Years",{"count":49,"type":50},100,"ESTIMATED","OBSERVATIONAL","Lupus Nephritis is one of the most severe organ manifestations of systemic lupus erythematosus and represents a major cause of morbidity, chronic kidney disease, and long-term mortality. Despite significant advances in immunosuppressive therapies, a substantial proportion of patients fail to achieve sustained renal remission or progress to end-stage renal disease, highlighting the need for improved understanding of disease mechanisms and more reliable biomarkers for disease monitoring and therapeutic response",[54],"Lupus Nephritis (LN)","NOT_YET_RECRUITING","2026-07-19",{"date":58,"type":59},"2026-07-23","ACTUAL",{"date":61,"type":50},"2026-09-01",{"date":63,"type":50},"2028-10-31",{"name":5,"class":6}]